A key challenge in the field of T-cell immunotherapy for cancer is creating a suitable platform for promoting differentiation of effector cells while at the same time enabling self-renewal needed for long-term memory. Although transfer of less differentiated memory T cells increases efficacy through greater expansion and persistence in vivo, the capacity of such cells to sustain effector functions within immunosuppressive tumor microenvironments may still be limiting. We have therefore directly compared the impact of effector versus memory differentiation of therapeutic T cells in tumor-bearing mice by introducing molecular switches that regulate cell fate decisions via mTOR. Ectopic expression of RAS homolog enriched in brain (RHEB) increased mTORC1 signaling, promoted a switch to aerobic glycolysis, and increased expansion of effector T cells. By rapidly infiltrating tumors, RHEBtransduced T cells significantly reduced the emergence of immunoedited escape variants. In contrast, expression of proline-rich Akt substrate of 40 kDa (PRAS40) inhibited mTORC1, promoted quiescence, and blocked tumor infiltration. Fate mapping studies following transient expression of PRAS40 demonstrated that mTORC1 low T cells made no contribution to initial tumor control but instead survived to become memory cells proficient in generating recall immunity. Our data support the design of translational strategies for generating heterogeneous T-cell immunity against cancer, with the appropriate balance between promoting effector differentiation and self-renewal. Unlike pharmacologic inhibitors, the genetic approach described here allows for upregulation as well as inhibition of the mTORC1 pathway and is highly selective for the therapeutic T cells without affecting systemic mTORC1 functions. Cancer Res; 75(13); 2641-52. Ó2015 AACR.
Introduction
A key challenge within the T-cell immunotherapy field is identifying a suitable strategy for inducing potent effector responses to eliminate cancerous cells without compromising the development of T-cell memory required for long-term immune surveillance. Recent fate mapping studies of immune responses have demonstrated a remarkable heterogeneity in the responses of individual na€ ve CD8 þ T cells and their progeny following a first and subsequent exposure to antigen (1, 2) . The initial clonal burst is composed primarily of short-lived effector cells that undergo multiple divisions, whereas cells that have low levels of expansion during the primary response acquire memory potential and contribute to the recall responses after subsequent secondary or tertiary antigen challenge; in this linear model of differentiation, memory cells have been stimulated the least during initial antigen encounters but upon rechallenge are highly efficient in generating new waves of effector cells as well daughter memory cells through self-renewal (1, 2) . In the adoptive immunotherapy setting, an inverse co-relation between T-cell differentiation and tumor immunity has been described; adoptive transfer of fully differentiated end stage effector cells was less effective than transfer of less differentiated T cells (3) . The inefficiency of fully differentiated effector cells was linked to poor in vivo expansion and survival (3), while less differentiated and memory-stem cells expanded and showed long-term persistence (4) (5) (6) (7) . Although these observations highlight the importance of transferring cells with the potential to expand and persist in vivo, the capacity of such cells to sustain effector functions in tumor-bearing hosts may still be limiting. Indeed, there is substantial evidence that the tumor microenvironment actively limits the efficacy of T-cell therapies by preventing effector differentiation (8, 9) . Thus, therapeutic strategies designed to enhance memory potential must also be evaluated in relation to their impact upon effector functions.
In this study, we used overexpression of RAS homolog enriched in brain (RHEB) and proline-rich Akt substrate of 40 kDa (PRAS40), two key molecules involved in positive and negative regulation of the mTORC1 pathway, respectively (10, 11) , to explore the relative roles of effector function and memory potential in a murine model of adoptive immunotherapy of cancer. The results revealed that overexpression of RHEB in tumor-specific T cells increased mTORC1 activity, promoted earlier tumor infiltration, and prevented disease progression resulting from immune escape. In contrast, transient overexpression of PRAS40 decreased mTORC1 activity and increased subsequent recall immunity. Together, the data indicate that RHEBand PRAS40-mediated tuning of mTORC1 can be used to enhance protective effector function and memory differentiation of tumorspecific T cells in vivo.
Materials and Methods

Mice
Experiments were performed in accordance with Home Office Guidance (Animals Scientific Procedures Act 1986) and approved by the local ethics committee. B6, B6.PL-Thy1a/CyJ (B6 Thy1.1), B6.SJL-Ptprca Pepcb/BoyJ (B6 CD45.1), and Thy1.1þ C57BL/6 Firefly Luciferase transgenic mice were bred in-house.
Cell lines
EL4-NP stably expressing the influenza A virus nucleoprotein (NP) was a kind gift from Dr. B. Stockinger (National Institute for Medical Research, London).
CD8 þ T-cell transduction
Purification of CD8 þ T cells and retroviral transduction was performed as described previously (12) .
Oxygen consumption rate and extracellular acidification rate measurements CD8 þ T cells were transduced with VC, RHEB, or PRAS40
vectors and selected using the mouse CD19 reporter. For oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) measurements, the Seahorse XF-24 metabolic extracellular flux analyzer (Seahorse Bioscience) was used. T cells were resuspended in serum-free unbuffered RPMI-1640 medium (Sigma-Aldrich) and plated onto Seahorse cell plates (6 Â 10 5 cells per well in 5 replicate wells) coated with Cell-Tak (BD Biosciences). An "In-Seahorse" activation protocol (13) was used to monitor changes in metabolism before and after T-cell activation with anti-mouse CD3 antibody (145-2C11; 1 mg/mL; BD Biosciences), which was directly applied onto plated cells via the instrument's multi-injection port 80 minutes after the experiment was initiated.
EL4-NP tumor challenge B6 mice were sublethally irradiated (5.5 Gy) and inoculated with 1 Â 10 6 EL4-NP (s.c.). Tumors were allowed to grow for 5 days before i.v. injection of 0.1 to 1 Â 10 5 T RHEB , T PRAS , or T VC (Thy-1.1 þ ). Tumor-free mice were rechallenged with 1 Â 10 6 (50 Gy) irradiated EL4-NP (i.p.). Bioluminescent imaging of T-cell infiltration of tumors was performed as described previously (12) .
Doxycycline induction in vitro and in vivo
In vivo induction of transgene expression in cells transduced with pSERS vectors was achieved by treatment with 2 mg/mL doxycycline in drinking water (Sigma-Aldrich).
Methods for flow cytometry and retroviral vector construction are outlined in the Supplementary Materials.
Results
Overexpression of RHEB and PRAS40 modulates T-cell metabolism and functions
To address the role of increased or reduced mTORC1 signaling in gene-engineered T cells, we transduced C57BL/6 (B6) purified CD8 þ splenocytes with retrovirus encoding codon-optimized Tcra and Tcrb genes for the F5 TCR (that recognizes the influenza-derived pNP366 peptide presented by H2-D b ), together with retrovirus encoding Rheb or Pras40 or a vector control construct to produce T cells referred to as T RHEB , T PRAS , and T VC , respectively (Fig. 1A) . To test the effect of overexpressing RHEB and PRAS40 on mTORC1 signaling following TCR activation, we stimulated transduced CD8
þ T cells with cognate antigen (EL4 thymoma cells expressing influenza NP protein) or with CD3/CD28 beads. T-cell stimulation triggers mTORC1 kinase activity, resulting in phosphorylation of direct targets including the eukaryotic translation initiation factor 4E-binding protein 1 (p-4E-BP1) and the ribosomal S6 kinase, which in turn phosphorylates ribosomal S6 proteins (p-S6; refs. 14, 15). We observed increased levels of p-S6 in T VC within 1 hour of stimulation with EL4-NP thymoma cells (Fig. 1B) . T RHEB showed augmented levels of p-S6, both at baseline and after antigen stimulation, whereas T PRAS showed diminished phosphorylation at baseline and following antigen stimulation (Fig. 1B) . At 24 hours after stimulation, T RHEB displayed increased, whereas T PRAS cells showed reduced p-S6 levels compared with vector control T cells (Fig. 1B and C) . We did not find increased levels of p-4E-BP1 in T RHEB , whereas diminished phosphorylation of the TORC1 target protein was seen in T PRAS (Fig. 1C) . Although overexpression of RHEB increased p-S6 levels at baseline and after antigen stimulation, this did not alter the sensitivity to inhibition by rapamycin, with similar IC 50 values observed for T RHEB , T PRAS , and T VC (Fig. 1D ). These data show that overexpression of RHEB and PRAS40 respectively enhances or suppresses mTORC1 signaling in CD8 þ T cells.
Consistent with the role for mTORC1 in promoting cell growth (16), nonstimulated T RHEB cells were larger in size than T VC cells, whereas T PRAS were smaller ( Fig. 2A) . Furthermore, even in the absence of stimulation, T RHEB had reduced surface expression of the lymph node homing molecule CD62L compared with control cells consistent with the inhibitory effect of mTORC1 upon CD62L transcription (17) , whereas T PRAS had increased CD62L expression (Fig. 2B) . Although we could detect no differences in cell viability between the groups (data not shown), we consistently observed reduced expression of activated caspase-3 in T PRAS compared with controls whereas expression was unchanged in T RHEB ( Supplementary Fig. S1 ). Upon stimulation in vitro, both T RHEB and T VC showed similar upregulation of the activation markers, CD69 and CD25 ( Supplementary Fig. S2 ). When we examined cell functions, T RHEB expressed similar levels of intracellular IFNg as control cells following stimulation (Fig. 2C ), but demonstrated increased specific cytotoxicity against EL4-NP cells (Fig. 2D ). In contrast, T PRAS showed both reduced intracellular IFNg and decreased cytotoxic functions relative to controls ( Fig. 2C and D) .
T-cell activation induces a shift from oxidative respiration to aerobic glycolysis, also known as the Warburg effect, a process regulated by mTORC1 (14) . We took real-time measurements of ECAR and OCR, which are molecular surrogates for glycolysis and respiration, respectively, before and after TCR stimulation with monoclonal anti-CD3 antibody. Compared with control cells, baseline ECAR was increased in T RHEB but decreased in T PRAS (Fig. 2E) . TCR stimulation resulted in rapid increases in ECAR for the three cell types, but it was augmented in T RHEB and diminished in T PRAS compared with T VC . Baseline oxygen consumption was also higher for T RHEB and lower for T PRAS ; following stimulation, T RHEB demonstrated a rapid decrease in OCR accentuating the shift from oxidative to glycolytic metabolism, whereas this rapid shift was not seen for T VC and T PRAS (Fig. 2E ). Taken together, these data demonstrate that overexpression of RHEB enhances T-cell effector differentiation as evidenced by increased cell growth, a switch to aerobic glycolysis and greater cytotoxicity, whereas overexpression of PRAS40 induces largely reciprocal effects.
The effect of RHEB and PRAS40 upon the kinetics of T-cell expansion and function in vivo
To assess how overexpression of RHEB and PRAS40 affects T-cell performance in vivo, we performed a competition assay where T VC were mixed in a 1:1 ratio with either T RHEB or T PRAS and injected into sublethally irradiated B6 mice (Fig. 3A) . Two days later, mice were vaccinated with irradiated EL4-NP cells to provide antigenic stimulation, and the frequency of transferred cells in cancerres.aacrjournals.org Downloaded from peripheral blood was monitored weekly. The two competing T-cell populations were distinguished by the expression of congenic markers Thy1.1 and Thy1.2 (Fig. 3A) . Vaccination with EL4-NP resulted in an increased frequency of F5 TCR þ T cells in peripheral blood followed by a sharp decline. During the initial expansion, T RHEB cells accumulated rapidly with a significant advantage over control cells as reflected by a high T RHEB :T VC ratio on day 7 (Fig. 3B) . However, this was followed by an accentuated and rapid contraction phase with a persistent disadvantage for T RHEB at all later time points (T RHEB :T VC ratio <1.0). In the other experimental arm, T PRAS demonstrated a relative failure to accumulate in peripheral blood after vaccination, resulting in a constant low T PRAS :T VC ratio (Fig. 3B) . In a similar experiment, we determined the phenotypic and functional profiles of T RHEB and T PRAS at 8 days following vaccination. As demonstrated in vitro, splenic T RHEB had reduced CD62L expression whereas T PRAS showed heightened expression compared with controls (Fig. 3C) . Expression of the terminal differentiation marker, killer cell lectin-like receptor subfamily G member 1, was similar in T RHEB and T VC , whereas T T VC and T PRAS : T VC ratios; Ã , P < 0.05 (one sample t test against a theoretical mean of 1). C-F, experimental layout as in A with responses analyzed at day 8 after vaccination. Data are from two independent experiments. C, surface expression of CD62L.
ÃÃ , P ¼ 0.002; ÃÃÃ , P ¼ 0.001 (two-tailed Wilcoxon matched pairs signed rank test). D, intracellular expression of T-bet and Eomes. Representative flow cytometry plots and summary data.
Ã , P ¼ 0.04; n.s., not significant (two-tailed Wilcoxon matched pairs signed rank test). E, proliferation of transduced CD8 þ T cells in vivo. Mice were injected with BrdUrd on day 7 and BrdUrd incorporation measured by flow cytometry. ÃÃÃ , P ¼ 0.001 (two-tailed Wilcoxon matched pairs signed rank test). F, cytokine production of transduced T cells following 4-hour stimulation ex vivo with 1 mmol/L pNP366. Representative flow cytometry plots showing IFNg and TNFa intracellular staining (left) and summary graph for IFNg production (right) with data from one of two independent experiments with similar results (n ¼ 6 mice/condition).
Ã , P ¼ 0.03; n.s., not significant (two-tailed Wilcoxon matched pairs signed rank test). demonstrated reduced expression (Supplementary Fig. S3 ). Consistent with published data for the expression of the T-box transcription factors in effector cells (18) , T RHEB were characterized by the increased number of cells that possessed high intracellular expression of T-bet but low expression of Eomesodermin (Eomes), while the frequency of T-bet high Eomes low cells was lower in T PRAS and T VC (Fig. 3D) . We evaluated in vivo proliferation by measuring BrdUrd incorporation. As shown in Fig. 3E , T RHEB demonstrated greater proliferation than control cells, whereas T PRAS were hypoproliferative. Upon ex vivo restimulation with antigen, T RHEB produced similar levels of IFNg and TNFa to T VC , whereas T PRAS consistently produced less (Fig. 3F) .
When T cells were tracked over a longer period following vaccination (to day 135), we found that T PRAS in the spleen and lymph node retained high expression levels of CD62L and CD127, markers associated central memory differentiation (Fig. 4A) . In contrast, both T VC and T RHEB populations had a greater proportion of CD62L low CD127 low cells. Thus, although the ratio of T PRAS to T VC was low when considered at a whole population level, the frequencies of cells with a central memory phenotype were similar (Fig. 4B ). In contrast, at both whole population and central memory level, the ratios of T RHEB to T VC were <1.0 (Fig. 4B ). Taken together, these data show that overexpression of RHEB drives the differentiation and rapid proliferation of short-lived T-bet high effectors in secondary lymphoid organs. On the other hand, constitutive overexpression of PRAS40 induces quiescence and the acquisition of a central memory phenotype.
T RHEB demonstrate enhanced early infiltration and antitumor effects
To address how mTORC1 activity affects control of tumor by CD8 þ T cells, we injected EL4-NP cells into the flanks of sublethally irradiated B6 mice and 5 days later adoptively transferred T VC , T RHEB , and T PRAS bearing the F5 TCR, or mock-transduced T cells. Tumors grew rapidly in mice receiving mock-transduced T cells with 100% lethality observed before day 20, while T VC controlled tumor growth in 60% of mice by day 60 (Fig. 5A ). Adoptive therapy with T RHEB improved tumor protection and resulted in 85% tumor-free survival by day 60. Consistent with their overall quiescence, T PRAS were completely unable to control tumor growth and behaved like mock-transduced cells with 100% lethality before day 20 (Fig. 5A) . Measurement of tumor size indicated that T RHEB reduced tumor burden more rapidly than T VC (Fig. 5B) . The reisolation of tumors that grew progressively in mice treated with T RHEB and T VC revealed that F5 TCR-transduced CD8 þ T cells were unable to recognize these re-isolates, although the same T cells efficiently recognized the parental EL4-NP tumor cells resulting in antigen-specific IFNg production (Fig. 5C ). The reisolated tumors continued to express H2-D b , indicating that the observed immune escape was not due to loss of MHC class I surface expression (Fig. 5C) .
To determine the extent to which manipulation of mTORC1 activity influenced the capacity of adoptively transferred CD8 þ T cells to infiltrate tumors, we transduced T cells from Firefly Luciferaseþ donors and measured their accumulation at the tumor site by bioluminescence at timed intervals following injection (Fig. 5D ). T RHEB infiltrated tumors significantly earlier than T VC with the median bioluminescence value being 2-fold greater at day 6, whereas T PRAS infiltration was significantly delayed with bioluminescence values $3-fold lower than controls. Furthermore, in contrast with their behavior in blood and secondary lymphoid organs, T RHEB numbers expanded at the tumor site over the course of the experiment. Together, these experiments showed that overexpression of RHEB increased the capacity of therapeutic T cells to rapidly infiltrate tumors and reduced the development of progressively growing immune escape variants, whereas constitutive overexpression of PRAS40 abolished protective tumor immunity. 
Long-term immune memory is impaired following constitutive overexpression of RHEB or PRAS40
To test how constitutive overexpression of RHEB or PRAS40 would affect the capacity of F5 TCR-transduced T cells to mount a recall response, we performed the competition experiment as outlined in Fig. 3 by cotransferring 1:1 mixes of either T RHEB with T VC or T PRAS with T VC into sublethally irradiated mice and then vaccinating them with EL4-NP cells on day 2. At day 40, we repeated the vaccination and tracked the response of transduced T cells in peripheral blood. As shown in Supplementary  Fig. S4 , T RHEB mounted a reduced but measurable recall response compared with T VC . Despite increased frequencies of T PRAS with a memory phenotype at day 40, no recall response was detectable in peripheral blood following revaccination, indicating that quiescence was permanently induced in this population ( Supplementary Fig. S4 ). In mice that had previously eradicated subcutaneous EL4-NP tumors and were later revaccinated, we observed a similar relative reduction in recall responsiveness of T RHEB ( Supplementary Fig. S4 ); no long-term survivors were observed in tumor-bearing recipients of T PRAS making analysis of memory responses in this context not possible. Taken together, these data show that fixing mTORC1 activity at high or low levels reduces recall responsiveness of CD8 þ T cells. 
Inducible PRAS40 expression during initial antigen encounter increases recall immunity
We reasoned that transient interruption of mTORC1 activity during the initial period of antigen exposure, followed by re-enablement of function at the time of recall, would increase recall immunity and the potential for durable immune surveillance. We therefore developed an inducible system for PRAS40 expression, by adapting a pSERS retroviral vector incorporating a Tet-ON "allin-one" inducible system for regulating gene expression ( Fig. 6A;  ref. 19) . The vector was modified to encode PRAS40 marked with GFP (iPRAS) or GFP alone (iGFP), under the control of a minimal promoter regulated by a Tet operon (TetO), which renders the promoter transcriptionally silent. The vector also encodes the reverse tetracycline-controlled transactivator (rtTA2-M2), which is marked by the Q8 surface tag (a 16-residue sequence of CD34 linked to a CD8 stalk; ref. 20) under the control of the constitutively active human PGK promoter. In the presence of doxycycline, rtTA2-M2 binds the TetO and promotes transcription of the gene of interest. Comparable dose-dependent induction of GFP expression was observed for both iPRAS and iGFP vectors with a maximum induction achieved with 1 mg/mL doxycycline (Supplementary Fig. S5) . To assess the effect of inducible PRAS40 expression on . Inducible PRAS40 expression during initial antigen encounter increases recall immunity. A, pSERS doxycycline-inducible vector maps. LTR, long terminal repeat; TetO7, tetracycline operator; FMD-2A, foot-and-mouth disease 2A sequence; hPGK, human phosphoglycerate kinase; rtA2-M2, optimized reverse tetracyclinecontrolled transactivator; W-PRE, Woodchuck hepatitis post-transcriptional regulatory element; P2A, picornavirus 2A sequence. B, T iGFP or T iPRAS were split in two lots, one receiving 1 mg/mL doxycycline (Dox) and the other left untreated. Twenty-four hours later, CD8 þ T cells were stimulated with anti-CD3/CD28 microbeads for further 24 hours and cells stained for p-S6. Flow cytometry plots shown are representative of three independent experiments and show GFP expression and p-S6 levels of both GFP þ and GFP À populations. C, sublethally irradiated B6 mice were inoculated with 1 Â 10 6 EL4-NP subcutaneously and divided in two cohorts, one receiving 2 mg/mL doxycycline in the drinking water and the other left untreated. Five days after tumor injection, mice received a 1:1 mix of T iGFP and T iPRAS that could be tracked with the congenic markers Thy1.1 and CD45.1, respectively. Doxycycline treatment was stopped at day 30 after tumor injection. At day 45, mice were rechallenged with irradiated EL4-NP (R). Tumor size during experiment (middle); data are representative of two independent experiments (n ¼ 3 mock and n ¼ 5 for þDox and no Dox groups). Mean AE SEM T iPRAS :T iGFP ratio in peripheral blood after rechallenge at day 45 (right). ) were treated with 1 mg/mL doxycycline for 24 hours, or left untreated, before being stimulated with EL4-NP cells (Fig. 6B) . In the absence of doxycycline, no GFP expression was detected in T iGFP and T iPRAS , and both cell types responded to stimulation by increasing the levels of p-S6 equally. Treatment with doxycycline induced GFP expression in both groups, but GFP þ cells from the T iPRAS group showed reduced levels of p-S6 compared with the GFP þ cells from the T iGFP group and the GFP À (un-induced) fraction of both groups (Fig. 6B) .
To test the effect of inducible PRAS40 overexpression in vivo, we inoculated sublethally irradiated B6 mice with subcutaneous EL4-NP tumors and divided the recipients into two cohorts, one receiving 2 mg/mL doxycycline in the drinking water and one left untreated; 5 days later, we adoptively transferred a 1:1 mix of T iPRAS with T iGFP (Fig. 6C) . The tumors were controlled to a similar extent in both the doxycycline (day 0-day 30) and no doxycycline groups (Fig. 6C) . To test recall immunity, we rechallenged mice in both groups with irradiated EL4-NP cells on day 45. Relative to controls, we observed significantly greater expansion of T iPRAS relative to T iGFP under conditions where they had been exposed to doxycycline during the initial response, whereas expansion of T iPRAS and T iGFP was similar in recipient mice that had not received doxycycline (Fig. 6C) .
In contrast with the constitutive pMP71-PRAS40 vector, where all transduced T cells were uniformly GFP high and mTORC1 was inhibited to a similar extent ( Supplementary Fig. S6 ), we found that doxycycline induced the GFP reporter in vitro at varying levels that were proportional to the Q8 tag (Fig. 7A) . Consistent with the inhibitory effects of PRAS40, S6 phosphorylation was inversely related to GFP expression in the T iPRAS group, with GFP high cells showing the greatest levels of inhibition and GFP low cells showing intermediate inhibition, whereas GFP neg cells behaved like controls. When we examined the fate of F5 TCR þ T-cell populations from each group in vivo in the presence of doxycycline, we consistently observed that expression of both the Q8 tag (marking cells transduced with the Tet-On vector) and the GFP reporter was much lower in T iPRAS than T iGFP (Fig. 7B) . Taken together, these data show that the initial response mediated by T iPRAS was characterized by in vivo selection for cells with low-rather than high-level inhibition of mTORC1.
Although outcompeted during the initial response, we reasoned that T iPRAS with higher levels of mTORC1 inhibition would be more efficient at transitioning to memory and would therefore contribute more to the recall response once the suppression of mTORC1 was relieved. This hypothesis could be tested in vivo because the Q8 tag identified T iPRAS populations that during initial antigen exposure in the presence of doxycycline had either low or high levels of mTORC1 inhibition and could therefore be used to map the fate of such cells at a later phase of the response. As shown in Fig. 7C , the proportion of Q8-expressing cells significantly increased from their initial low level among the F5 TCR þ population upon withdrawal of doxycycline and following antigenic rechallenge. In contrast, no changes in Q8 expression were noted in the group that received no doxycycline. Thus, T iPRAS memory recall responses were derived mainly from low frequency cells with higher levels of mTORC1 inhibition during initial antigen encounter.
Discussion
By direct comparison in the same model systems, our data show for the first time a role for enhancement as well inhibition of intrinsic mTORC1 function in generating effective antitumor responses by T cells. Enhanced mTORC1 activity accelerated Tcell infiltration at the tumor site and exerted more aggressive immune pressure on the growing tumors, which was associated with a reduction in the selection of tumor escape variants driving progressive disease.
Our data also show that levels of RHEB are limiting for full mTORC1 activation and maximal effector differentiation following TCR activation. In sharp contrast with the peripheral blood and lymphoid organs where T RHEB expanded rapidly but were only short-lived, T RHEB infiltration of EL4-NP was sustained over the course of at least 2 weeks. These data highlight the need to evaluate T-cell responses both within tumors and secondary lymphoid organs where manipulation of mTORC1 activity may have distinct effects. Our findings are also in accordance with recent studies demonstrating that enhanced glycolytic capacity of effector CD8 þ T cells is linked to increased antitumor immunity (21, 22) . As antitumor T cells begin to infiltrate tumors, they encounter multiple factors likely to inactivate mTORC1 (8, 9) . For example, tumor-associated myeloid cells upregulate the arginase pathway to deplete the microenvironment of arginine, leading to impaired T-cell functions (23, 24) . In this context, we have observed that overexpression of RHEB increases resistance of proliferating T cells to arginine depletion in vitro (data not shown) indicative that T RHEB have greater fitness in contexts where mTORC1 activity would ordinarily be suppressed.
Failure of transferred T cells to persist or to be replenished through self-renewal may lead to relapse (25) (26) (27) , particularly under conditions where transforming stimuli remain (e.g., from viruses) or where the initial response cannot eliminate all cancerous cells and long-term immune surveillance is required to keep them in check. Previous studies have demonstrated that using rapamycin to reduce mTORC1 signaling in a responding CD8 þ T-cell population can improve memory potential and antiviral or antitumor immunity (18, 28) , although the extent to which this strategy works while also maintaining the capacity for an effector response is highly variable and dependent upon the model systems studied (29) (30) (31) . Furthermore, this strategy may be complicated by systemic "on target" effects of the drug, for example enhancement of Treg expansion (29) (30) (31) (32) . Our data show that constitutive mTORC1 inhibition through overexpression of PRAS40 increases formation of memory phenotype CD127 þ
CD62L
þ CD8 þ T cells; however, the transduced cells enter a state of permanent quiescence incapable of generating effector cells either during the primary response or recall. Indeed, although knockdown of RAPTOR and MTOR (both components of the mTORC1 complex) has been shown to enhance memory differentiation of CD8 þ T cells (28), we have found that such cells were incapable of expansion following transfer to tumor-bearing hosts ( Supplementary Fig. S7 ). Thus, inhibition of mTORC1 with rapamycin may be most effective at enhancing antitumor CD8 þ T-cell immunity when employed at low doses that do not ablate the initial expansion of effector cells (28) or when it is curtailed early following priming to maximize secondary effector responses (18, 31) . In contrast with the constitutive expression system where PRAS40 expression was uniformly high, PRAS40 was induced across a range of values using the Tet-ON system. Upon transfer in vivo, T cells with higher levels of PRAS40 were rapidly outcompeted by effector cells where the protein had been induced at lower levels. However, low-frequency memory precursor cells, characterized by higher levels of initial mTORC1 inhibition, survived and reconstituted the secondary response when mTORC1 signaling was no longer suppressed. Our findings are consistent with recent fate mapping studies for (33) . In summary, our data support the design of translational strategies that generate heterogeneous T-cell immunity with the appropriate balance between self-renewal and effector differentiation. Precise clinical application of this approach will require further dissection of how mTOR functions of adoptively transferred T cells are modulated in the tumor environment of individual cancer types and at different stages of disease.
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